Eloxx reports PhII cystic fibrosis fail as the biotech weighs its options
A rare disease biotech has fallen short in a clinical trial — and investors are none too happy about it.
Eloxx Pharmaceuticals reported Wednesday that its small molecule candidate ELX-02 combined with ivacaftor failed a small Phase II trial. The combination trial tested the two drugs in patients with Class 1 cystic fibrosis and at least one “nonsense mutation.” Ivacaftor is one-half of Vertex’s cystic fibrosis blockbuster drug Orkambi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.